X-Linked Retinitis Pigmentosa (XLRP)
Symptoms, Doctors, Treatments, Advances & More

X-Linked Retinitis Pigmentosa (XLRP) Overview

Save information for later
Sign Up

Learn About X-Linked Retinitis Pigmentosa (XLRP)

View Main Condition: Retinitis Pigmentosa

What is the definition of X-Linked Retinitis Pigmentosa (XLRP)?
X-linked retinitis pigmentosa is a type of inherited eye disorder that affects the retina, causing progressive vision loss. X-linked retinitis pigmentosa is classified as non-syndromic because it occurs by itself instead of as part of other syndromes.
What are the symptoms of X-Linked Retinitis Pigmentosa (XLRP)?
Symptoms of X-linked retinitis pigmentosa include a loss of night vision in childhood; blind spots in the side, or peripheral, vision; tunnel vision; loss of central vision; and, eventually, blindness.
Not sure about your diagnosis?
Check Your Symptoms
What are the current treatments for X-Linked Retinitis Pigmentosa (XLRP)?
Treatment for X-linked retinitis pigmentosa involves the use of gene therapy made from adeno-associated viral vectors.
Who are the top X-Linked Retinitis Pigmentosa (XLRP) Local Doctors?
Elite in X-Linked Retinitis Pigmentosa (XLRP)
Dr. Abigail T. Fahim
Ophthalmology
Elite in X-Linked Retinitis Pigmentosa (XLRP)
Dr. Abigail T. Fahim
Ophthalmology

Kellogg Eye Center

1000 Wall St, Elevator B Floor 2, 
Ann Arbor, MI 
734-763-5874
Experience:
17+ years
Languages Spoken:
English
See accepted insurances

Abigail Fahim is an Ophthalmologist practicing medicine in Ann Arbor, Michigan. She has been practicing medicine for over 17 years. Dr. Fahim is rated as an Elite provider by MediFind in the treatment of X-Linked Retinitis Pigmentosa (XLRP). She is also highly rated in 29 other conditions, according to our data. Her clinical expertise encompasses X-Linked Retinitis Pigmentosa (XLRP), Retinitis Pigmentosa, Retinopathy Pigmentary Mental Retardation, and Usher Syndrome Type 2A. Dr. Fahim is board certified in Ophthalmology.

Elite in X-Linked Retinitis Pigmentosa (XLRP)
Tom R. Denee
Elite in X-Linked Retinitis Pigmentosa (XLRP)
Tom R. Denee
Breda, NB, NL 

Tom Denee practices practicing medicine in Breda, Netherlands. Mr. Denee is rated as an Elite expert by MediFind in the treatment of X-Linked Retinitis Pigmentosa (XLRP). He is also highly rated in 4 other conditions, according to our data. His clinical expertise encompasses X-Linked Retinitis Pigmentosa (XLRP), Retinopathy Pigmentary Mental Retardation, Retinitis Pigmentosa, and Late-Onset Retinal Degeneration.

 
 
 
 
Learn about our expert tiers
Learn More
Elite in X-Linked Retinitis Pigmentosa (XLRP)
Michel Michaelides
Elite in X-Linked Retinitis Pigmentosa (XLRP)
Michel Michaelides
City Road, 
London, ENG, GB 

Michel Michaelides practices practicing medicine in London, United Kingdom. Mr. Michaelides is rated as an Elite expert by MediFind in the treatment of X-Linked Retinitis Pigmentosa (XLRP). He is also highly rated in 40 other conditions, according to our data. His clinical expertise encompasses Retinopathy Pigmentary Mental Retardation, Color Blindness, Retinitis Pigmentosa, Vitrectomy, and Cataract Removal.

View All Doctors
What are the latest X-Linked Retinitis Pigmentosa (XLRP) Clinical Trials?
A Phase 2 Open-label Study to Evaluate the Safety of Laruparetigene Zovaparvovec Administered Bilaterally in Male Participants With X-Linked Retinitis Pigmentosa
A Phase 2 Open-label Study to Evaluate the Safety of Laruparetigene Zovaparvovec Administered Bilaterally in Male Participants With X-Linked Retinitis Pigmentosa
Enrollment Status: Recruiting
Publish Date: February 19, 2026
Intervention Type: Biological
Study Phase: Phase 2

Summary: The purpose of this Phase 2 Study is to see if the investigational study drug, laruparetigene zovaparvovec, also known as AGTC-501, given in both eyes, is safe and works to preserve and/or improve vision and other symptoms of XLRP.

Match to trials
Find the right clinical trials for you in under a minute
Get started
A Phase I/II Dose-escalation and Dose-expansion Study to Evaluate the Safety and Efficacy of FT-002 Subretinal Injection in Subjects With RPGR Gene Mutation-associated X-linked Retinitis Pigmentosa.
A Phase I/II Dose-escalation and Dose-expansion Study to Evaluate the Safety and Efficacy of FT-002 Subretinal Injection in Subjects With RPGR Gene Mutation-associated X-linked Retinitis Pigmentosa.
Enrollment Status: Recruiting
Publish Date: July 09, 2024
Intervention Type: Genetic
Study Phase: Phase 1/Phase 2

Summary: The aim of this study was to evaluate the safety, tolerability, and efficacy of one-time subretinal injection of FT-002 in male subjects (8-45 years of age) with RPGR (Retinitis Pigmentosa GTPase Regulator) gene mutation-associated X-linked retinitis pigmentosa, of XLRP. This study includes Phase I (dose escalation phase) and Phase II (dose expansion phase).

View All Clinical Trials